Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Pangan, Aileen L"'
Autor:
Kaeley GS; From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.; G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles., MacCarter DK; From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.; G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles., Pangan AL; From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.; G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles., Wang X; From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.; G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles., Kalabic J; From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.; G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles., Ranganath VK; From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. vranganath@mednet.ucla.edu.; G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. vranganath@mednet.ucla.edu.
Publikováno v:
The Journal of rheumatology [J Rheumatol] 2018 Dec; Vol. 45 (12), pp. 1628-1635. Date of Electronic Publication: 2018 Sep 01.
Autor:
Mease PJ; From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. pmease@philipmease.com.; P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. pmease@philipmease.com.; P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. pmease@philipmease.com., Van den Bosch F; From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.; P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB.; P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc., Sieper J; From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.; P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB.; P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc., Xia Y; From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.; P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB.; P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc., Pangan AL; From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.; P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB.; P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc., Song IH; From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.; P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB.; P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc.
Publikováno v:
The Journal of rheumatology [J Rheumatol] 2017 May; Vol. 44 (5), pp. 599-608. Date of Electronic Publication: 2017 Mar 15.
Autor:
Maksymowych WP; Alberta Heritage Foundation for Medical Research, Edmonton, Alberta T6G 2S2, Canada. walter.maksymowych@ualberta.ca., Lambert RG, Brown LS, Pangan AL
Publikováno v:
The Journal of rheumatology [J Rheumatol] 2012 Aug; Vol. 39 (8), pp. 1666-74. Date of Electronic Publication: 2012 Jul 01.
Autor:
Keystone EC; Division of Advanced Therapeutics, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, 60 Murray Street, Toronto, Ontario, Canada. edkeystone@mtsinai.on.ca, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL
Publikováno v:
The Journal of rheumatology [J Rheumatol] 2011 May; Vol. 38 (5), pp. 855-62. Date of Electronic Publication: 2011 Feb 01.
Autor:
van der Heijde D; Leiden University Medical Center, Leiden, The Netherlands., Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL
Publikováno v:
The Journal of rheumatology [J Rheumatol] 2010 Nov; Vol. 37 (11), pp. 2237-46. Date of Electronic Publication: 2010 Oct 01.